BCM
TXG icon

BlueCrest Capital Management’s 10x Genomics TXG Stock Holding History

BlueCrest Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,704
Closed -$539K – 590
2019
Q3 		$539K Buy
+10,704
New +$592K 0.04% 257

Other funds holding TXG

FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BlueCrest Capital Management's TXG Position: Q4 2019 in Review

BlueCrest Capital Management sold out of 10x Genomics (TXG) in Q4 2019, closing a stake of 10,704 shares — an estimated $539K sold.

BlueCrest Capital Management first reported a position in TXG in Q3 2019 and held it in 1 quarter. The position peaked at $539K in Q3 2019. 85 funds tracked by Wall St. Rank hold TXG as of Q4 2019.

  • BlueCrest Capital Management reported no remaining 10x Genomics position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,704 10x Genomics shares in Q4 2019, an estimated $539K.
  • BlueCrest Capital Management first reported a position in 10x Genomics in Q3 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's 10x Genomics position peaked at $539K in Q3 2019.
  • 85 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.